Showing results (1-10 of 412) with videos related to
Sort By:
Pageof 42
American Journal of Hematology|February 9, 2023
Complement-targeted therapeutics: An emerging field enabled by academic drug discoveryChristina Lamers, Daniel Ricklin, John D LambrisTrends in Pharmacological Sciences|January 29, 2022
Compstatins: the dawn of clinical C3-targeted complement inhibitionChristina Lamers, Dimitrios C Mastellos, Daniel Ricklin, et al.Advances in Experimental Medicine and Biology|September 20, 2012
Progress and Trends in Complement TherapeuticsDaniel Ricklin, John D LambrisAdvances in Experimental Medicine and Biology|November 26, 2008
Compstatin: a complement inhibitor on its way to clinical applicationDaniel Ricklin, John D LambrisImmunobiology|June 24, 2015
Therapeutic control of complement activation at the level of the central component C3Daniel Ricklin, John D LambrisJournal of Immunology (Baltimore, Md. : 1950)|April 9, 2013
Complement in immune and inflammatory disorders: therapeutic interventionsDaniel Ricklin, John D LambrisJournal of Immunology (Baltimore, Md. : 1950)|April 9, 2013
Complement in immune and inflammatory disorders: pathophysiological mechanismsDaniel Ricklin, John D LambrisSeminars in Immunology|June 21, 2016
New milestones ahead in complement-targeted therapyDaniel Ricklin, John D LambrisProceedings of the National Academy of Sciences of the United States of America|October 5, 2017
Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4HongBin Wang, Daniel Ricklin, John D LambrisPageof 42